Prosonix appoints chief medical officer

Oxford firm hires respiratory drug development expert Dr Geoff Down

Prosonix, an emerging pharmaceutical company based in Oxford, UK, has appointed Dr Geoff Down to the newly created role of chief medical officer. Down will oversee the clinical development of Prosonix’s respiratory product pipeline, including PSX1001, PSX1002 and the new PSX2000 combination series.

Down has more than 18 years’ clinical development experience in the pharmaceutical sector, following 10 years in clinical practice.

He joins Prosonix after running his own company, providing services as a consultant pharmaceutical physician. During this period he worked in clinical safety for Pfizer r&d, in clinical development for RespiVert Ltd (a spinout from Imperial Innovations that aims to identify new treatments for COPD, cystic fibrosis and severe asthma), and since December 2010 he has been working in clinical pharmacology at GlaxoSmithKline’s r&d Respiratory and Immuno-Inflammation medicines development centre (GSK RII MDC).

Dr Down has been a principal investigator or company sponsor for more than 50 early clinical development studies, including first-in-human studies, and in excess of 30 full clinical development trials.

You may also like

Research & Development

Proposed acquisition of Aerocrine and Prosonix by Circassia Pharmaceuticals

Creating a world-class speciality pharmaceutical allergy and asthma business
Research & Development

Prosonix receives £1.3m grant from the Biomedical Catalyst

To accelerate development of Multi-component particle (MCP) based combination respiratory medicines
Research & Development

Prosonix collaboration to speed up development of respiratory medicines

Prosonix and Imperial College London to accelerate development of engineered Multi-component Particles
Drug Delivery

Prosonix develops multi-component drug particles combining two respiratory drugs

To ensure optimal co-localisation in the lung
Research & Development

Prosonix offers co-crystal development service

Aimed at the manufacturing of co-crystals for use in inhaled and oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Subscribe now